Providence Saint Joseph Medical Center - Burbank

Summary

Providence Saint Joseph Medical Center - Burbank is a medical facility located in Burbank, California. This center is recognized for care of Lung Cancer, Lymphoma, Breast Cancer, Pancreatic Cancer, Non-Hodgkin's Lymphoma and other specialties. Providence Saint Joseph Medical Center - Burbank is involved with conducting 97 clinical trials across 108 conditions. There are 1 research doctors associated with this hospital, such as Karlton Wong.

Top PIs

Clinical Trials running at Providence Saint Joseph Medical Center - Burbank

Bladder Cancer

Transitional Cell Carcinoma

Hospital Acquired Infections

Central Line Bloodstream Infection

Disitamab Vedotin + Pembrolizumab vs Chemotherapy

for Bladder Cancer

This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.

Recruiting

2 awards

Phase 3

Disitamab Vedotin + Pembrolizumab

for Bladder Cancer

This trial is testing a new drug called disitamab vedotin, alone or with pembrolizumab, for patients with advanced or metastatic HER2 expressing bladder cancer. Disitamab vedotin is designed to target HER2 and has been approved for other types of cancer. The study aims to see if these drugs can effectively treat the cancer and what side effects they might cause.

Recruiting

1 award

Phase 2

4 criteria